FIELD: medicine.
SUBSTANCE: the present innovation refers to isolated human antibodies against peptides being the derivatives of apolipoprotein B. It is necessary to apply isolated human antibody or antibody fragment indicated to, at least, one oxidized fragment of apolipoprotein B, in manufacturing pharmaceutical composition for either therapeutic or prophylactic treatment of atherosclerosis due to immunization. The advantage of the present innovation lies in the fact that passive immunization has been occurred with pre-developed antibodies indicated to the same peptides. Moreover, as the applied antibodies are being completely human ones, the risk of unfavorable immunological reaction during the process of their introducing to a patient is decreased.
EFFECT: higher efficiency.
72 cl, 18 dwg, 5 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOTHERAPEUTIC TREATMENT | 2006 |
|
RU2454428C2 |
| PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
| PCSK9 ANTAGONISTS | 2014 |
|
RU2618869C2 |
| MONOCLONAL ANTIBODY CAPABLE OF NEUTRALIZING BIOLOGICAL ACTIVITY OF HUMAN INTERFERON BETA 1A | 2018 |
|
RU2729391C2 |
| LOX1-SPECIFIC BINDING PROTEINS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764993C2 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| METHOD FOR GM-CSFRα INHIBITION IN PATIENT | 2012 |
|
RU2639546C2 |
| STRUCTURE OF POLYPEPTIC ANTIBODIES | 2015 |
|
RU2725812C2 |
| ANTIBODY AGAINST LIPOARABINOMANNAN AND IMMUNOASSAY OF INFECTIONS CAUSED BY ACID-FAST BACILLI, USING ANTIBODY | 2013 |
|
RU2588480C2 |
